EP1401800A1 - Neues verfahren zur herstellung von (1s cis) 4 (3,4 dichlorphenyl) 1,2,3,4-tetrahydro-n-methyl-1-naphthalinamin - Google Patents
Neues verfahren zur herstellung von (1s cis) 4 (3,4 dichlorphenyl) 1,2,3,4-tetrahydro-n-methyl-1-naphthalinaminInfo
- Publication number
- EP1401800A1 EP1401800A1 EP02743288A EP02743288A EP1401800A1 EP 1401800 A1 EP1401800 A1 EP 1401800A1 EP 02743288 A EP02743288 A EP 02743288A EP 02743288 A EP02743288 A EP 02743288A EP 1401800 A1 EP1401800 A1 EP 1401800A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cis
- dichlorophenyl
- tetrahydro
- naphthalenamine
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title claims description 8
- 238000005695 dehalogenation reaction Methods 0.000 claims abstract description 26
- 239000003054 catalyst Substances 0.000 claims abstract description 23
- 239000003112 inhibitor Substances 0.000 claims abstract description 21
- 229960002073 sertraline Drugs 0.000 claims abstract description 13
- HVLLSGMXQDNUAL-UHFFFAOYSA-N triphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 claims abstract description 12
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 claims abstract description 5
- MGBVAZJASCWJGJ-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-n-methyl-3,4-dihydro-2h-naphthalen-1-imine Chemical compound C12=CC=CC=C2C(=NC)CCC1C1=CC=C(Cl)C(Cl)=C1 MGBVAZJASCWJGJ-UHFFFAOYSA-N 0.000 claims abstract description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 claims description 11
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 6
- 229910052763 palladium Inorganic materials 0.000 claims description 6
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical group O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 claims description 6
- VGKDLMBJGBXTGI-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C12=CC=CC=C2C(NC)CCC1C1=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 150000003003 phosphines Chemical class 0.000 claims description 4
- FEVFLQDDNUQKRY-UHFFFAOYSA-N tris(4-methylphenyl) phosphite Chemical compound C1=CC(C)=CC=C1OP(OC=1C=CC(C)=CC=1)OC1=CC=C(C)C=C1 FEVFLQDDNUQKRY-UHFFFAOYSA-N 0.000 claims description 4
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 238000005984 hydrogenation reaction Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 150000002466 imines Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000006227 byproduct Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229910002804 graphite Inorganic materials 0.000 description 4
- 239000010439 graphite Substances 0.000 description 4
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 2
- RZPFVRFSYMUDJO-UHFFFAOYSA-N 2h-naphthalen-1-one Chemical compound C1=CC=C2C(=O)CC=CC2=C1 RZPFVRFSYMUDJO-UHFFFAOYSA-N 0.000 description 2
- -1 3 , 4 -DICHLOROPHENYL Chemical class 0.000 description 2
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 229960003660 sertraline hydrochloride Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006704 dehydrohalogenation reaction Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- BLFQGGGGFNSJKA-XHXSRVRCSA-N sertraline hydrochloride Chemical compound Cl.C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 BLFQGGGGFNSJKA-XHXSRVRCSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- IFXORIIYQORRMJ-UHFFFAOYSA-N tribenzylphosphane Chemical compound C=1C=CC=CC=1CP(CC=1C=CC=CC=1)CC1=CC=CC=C1 IFXORIIYQORRMJ-UHFFFAOYSA-N 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- RXJKFRMDXUJTEX-UHFFFAOYSA-N triethylphosphine Chemical compound CCP(CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-N 0.000 description 1
- IGNTWNVBGLNYDV-UHFFFAOYSA-N triisopropylphosphine Chemical compound CC(C)P(C(C)C)C(C)C IGNTWNVBGLNYDV-UHFFFAOYSA-N 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
- C07C209/70—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by reduction of unsaturated amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
- C07C209/86—Separation
- C07C209/88—Separation of optical isomers
Definitions
- the present invention relates to a novel process for the preparation of (1S- cis)-4-(3 ,4-dichlorophenyl)- 1 ,2,3 ,4-tetrahydro-N-methyl- 1 -naphthalenamine (sertraline) comprising hydrogenation of N-[4-(3,4-dichlorophenyl)-3,4-dihydro- 5 1 (2H)-naphthalenylidene]methanamine.
- One object of the present invention is to provide an improved preparation method for cis-sertraline or a pharmaceutically acceptable acid addition salt thereof.
- the other object of the present invention is the pharmaceutical composition comprising cis-sertraline or a pharmaceutically acceptable acid addition salt thereof made by the process of the invention.
- the present invention provides a process for the preparation of cis-sertraline comprising hydrogenating N-[4-(3,4-dichlorophenyl)-3,4-dihydro-l(2H)- naphthalenylidene]methanamine in the presence of a catalyst and a dehalogenation inhibitor to achieve cis-racemate of 4-(3,4-dichlorophenyl)-l,2,3,4-tetrahydro-N- methyl- 1 -naphthalenamine.
- the ratio of cis:trans isomers is improved to as high as 97:3 and the formation of dehalogenation byproducts may be reduced to even less than 0.1 %. No further purification process is needed before resolution or crystallization. This is achieved by using the inhibitors of the invention in the hydrogenation process.
- Cis-sertraline is prepared starting from 4-(3 ,4-dichlorophenyl)-3 ,4-dihy dro- 1 -
- (2H)-naphthalenone (tetralone), which can be prepared by methods known in the art, e.g. as decsribed in US 5,019,655. Tetralone is reacted with monomethylamine to form an imine, which can be performed by methods known in the art, e.g. as described in US 4,536,518.
- the imine obtained is further hydrogenated to cis- racemate of 4-(3 ,4-dichlorophenyl)- 1 ,2,3 ,4-tetrahydro-N-methyl- 1 -naphthalenamine in the presence of a catalyst and a dehalogenation inhibitor of the invention. From this mixture, the cis-compound can be either resolved by e.g.
- the hydrogenation of the imine is performed in the presence of a catalyst and an inhibitor, which is selected from the group consisting of hypophosphorous acid, esters of hypophosphorous acid, phosphorous acid, esters of phosphorous acid, phosphine and substituted phosphines.
- Suitable inhibitors are e.g. mono-,di- and triesters of phosphorous acid, preferably trimethyl phosphite, triphenyl phosphite or tritolyl phosphite.
- suitable phosphines are e.g. trimethylphosphine, triethylphosphine, triisopropylphosphine, tritolylphosphine and tribenzylphosphine.
- the amount of the inhibitor used in the process is typically 0.5 - 10 mol %, preferably 3 - 5 mol %, based on the number of moles of the metal in the catalyst used.
- the catalyst used can be any suitable catalyst known in the art, e.g. palladium on carbon, palladium on graphite, palladium on carbon paste or PtO 2 .
- the catalyst is typically used in the amount of 0.1 - 1.0 % (w/w, calculated as the pure metal in the catalyst) based on the weight of the imine used.
- the hydrogenation may be carried out in an organic solvent, which can be any suitable protic or aprotic solvent or mixtures thereof. Examples of solvents are e.g.
- dimethylformamide DMF
- esters like ethyl acetate, chlorinated hydrocarbons like methylene chloride or chloroform, or alcohols like methanol, ethanol or isopropanol.
- alcohols like methanol, ethanol or isopropanol.
- a lower alcohol e.g. methanol or ethanol or their mixture with DMF is used as a solvent.
- the reaction can be carried out at a temperature of 0-100 °C, preferably at 20 - 50 °C.
- the hydrogen pressure used is from 1 to 50 bar, preferably from 2 to 5 bar.
- the reaction time can vary from half an hour to 24 hours depending on the catalyst used, on hydrogen pressure, on the reaction temperature and on the equipment used.
- the hydrogenation time is about 2 to 6 hours.
- N-[4-(3,4-dichlorophenyl)-3,4-dihydro-l-(2H)-naphthalenylidene]-methanamine 50 g
- methanol 300 ml
- palladium on graphite 5 % 2.5 g
- trimethyl phosphite 0.004 g
- the reaction mixture is hydrogenated at 5 bar overpressure of hydrogen for 5 hours at about 40 °C.
- the catalyst is removed by filtration and the cake is washed with methanol.
- the cis:trans ratio is 97:3.
- the amount of dehalogenation byproducts is ⁇ 0.1 %.
- the reaction mixture can be used directly in the resolution step or crystallized as HC1 salt.
- N-[4-(3,4-Dichlorophenyl)-3,4-dihydro-l(2H)-naphthalenylidene]methanamine 40 g
- dimethylformamide 150 ml
- methanol 150 ml
- palladium on graphite catalyst 4 g
- triphenyl phosphite 0.0010 g
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29808801P | 2001-06-15 | 2001-06-15 | |
| FI20011271 | 2001-06-15 | ||
| FI20011271A FI20011271A0 (fi) | 2001-06-15 | 2001-06-15 | Valmistusmenetelmä |
| US298088P | 2001-06-15 | ||
| PCT/FI2002/000518 WO2002102761A1 (en) | 2001-06-15 | 2002-06-14 | A novel process for the preparation of (is-cis) -4-(3, 4-dichlorophenyl) -1, 2, 3, 4 - tetrahydro-n-methyl-1-naphthalenamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1401800A1 true EP1401800A1 (de) | 2004-03-31 |
Family
ID=26161186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02743288A Withdrawn EP1401800A1 (de) | 2001-06-15 | 2002-06-14 | Neues verfahren zur herstellung von (1s cis) 4 (3,4 dichlorphenyl) 1,2,3,4-tetrahydro-n-methyl-1-naphthalinamin |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1401800A1 (de) |
| CA (1) | CA2448499A1 (de) |
| WO (1) | WO2002102761A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2522534A1 (en) | 2003-04-14 | 2004-10-28 | Teva Pharmaceutical Industries Ltd. | Hydrogenation of imine intermediates of sertraline with catalysts |
| WO2005121074A2 (en) * | 2004-06-09 | 2005-12-22 | Ranbaxy Laboratories Limited | Processes for the preparation of sertraline hydrochloride |
| GB0526444D0 (en) * | 2005-12-23 | 2006-02-08 | Sandoz Ag | Sertraline acid addition salt, its prepartion and its use in the preparation of sertraline hydrochloride form ll |
| TR200808115T1 (tr) * | 2006-04-28 | 2009-03-23 | Sandoz Ag | 4(S,R)-(3,4-diklorofenil)-3,4-dihidro-l(2H)-naftalin-l-ilid n]metilamin'ın Hazırlanması için Proses.@ |
| CN111632400B (zh) * | 2020-06-21 | 2022-04-05 | 赤峰制药股份有限公司 | 一种烯胺盐重结晶纯化方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3474144A (en) * | 1966-08-17 | 1969-10-21 | Gaf Corp | Catalytic reduction of chloronitro aromatic compounds |
| US4020107A (en) * | 1975-04-07 | 1977-04-26 | E. I. Du Pont De Nemours And Co. | Catalytic reduction of halonitroaromatic compounds |
| US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| IT1205040B (it) * | 1987-05-28 | 1989-03-10 | Rimar Chimica Spa | Processo per la riduzione catalitica di nitroalogenoderivati aromatici |
| HU226424B1 (en) * | 1998-05-05 | 2008-12-29 | Egis Gyogyszergyar Nyrt | Process for producing enantiomer mixture for preparation of sertraline |
| CN1232481C (zh) * | 2000-03-14 | 2005-12-21 | 特瓦制药工业有限公司 | 制备(+)－顺－舍曲林的方法 |
-
2002
- 2002-06-14 EP EP02743288A patent/EP1401800A1/de not_active Withdrawn
- 2002-06-14 WO PCT/FI2002/000518 patent/WO2002102761A1/en not_active Application Discontinuation
- 2002-06-14 CA CA002448499A patent/CA2448499A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO02102761A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2448499A1 (en) | 2002-12-27 |
| WO2002102761A1 (en) | 2002-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1224159B1 (de) | Racemisch sertralin synthese | |
| KR100704590B1 (ko) | (+)-시스-세르트랄린의 신규한 제조 방법 | |
| AP956A (en) | Novel process for preparing ketimine. | |
| AU767319B2 (en) | Process for preparing sertraline from chiral tetralone | |
| EP1401800A1 (de) | Neues verfahren zur herstellung von (1s cis) 4 (3,4 dichlorphenyl) 1,2,3,4-tetrahydro-n-methyl-1-naphthalinamin | |
| US6723878B2 (en) | Method for preparing sertraline | |
| WO2001016089A1 (en) | A process for the preparation of cis-(1s,4s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine hydrochloride | |
| WO2020165672A1 (en) | Process for preparation of highly pure fingolimod hydrochloride | |
| CA2576097C (en) | A highly stereoselective synthesis of sertraline | |
| EP1503978A1 (de) | Verfahren zur herstellung von sertralin | |
| US6121492A (en) | Method for preparing 2-trifluoro-methoxy-aniline | |
| US6930205B2 (en) | Process for preparing aminostilbene derivatives | |
| US20030013768A1 (en) | Process for the production of sertraline and intermediates useful therefor | |
| WO2002096860A1 (en) | Process for preparing sertraline intermediates | |
| WO2010076763A2 (en) | An improved process for the manufacture of sertraline | |
| JP2004352654A (ja) | ４−アミノシクロヘキサンカルボン酸アルキルエステル類のシス／トランス異性体混合物の分離方法 | |
| JPH10506380A (ja) | Ｏ−（２−ヒドロキシアルキル）オキシムの製造方法 | |
| EP2448911A1 (de) | Verfahren zur herstellung von 1-chloracetamid-1,3,3,5,5-pentamethylcyclohexan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20031215 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ORION CORPORATION |
|
| 17Q | First examination report despatched |
Effective date: 20071114 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20080102 |